Source comparison
MK-677 for Perimenopause: Comparing Research vs Clinical Application
Bone mineral density Modest increase in formation markers; density changes not statistically significant in 12-month trials Hypothesized benefit for osteopenia prevention in women 45–55, but no fracture outcome data IGF-1 stimulation of osteoblasts + increased
This comparison does not assign a generated winner or score.
- Bone mineral density
- Modest increase in formation markers; density changes not statistically significant in 12-month trials
- Hypothesized benefit for osteopenia prevention in women 45–55, but no fracture outcome data
- IGF-1 stimulation of osteoblasts + increased lean mass creating mechanical bone loading
- Bone remodeling requires 18–24 months to show measurable density changes; most trials run ≤12 months
- Promising biochemical signal, but insufficient evidence to replace bisphosphonates or HRT for bone protection
- Lean body mass
- +1.1kg lean mass over 12 months in elderly subjects, independent of exercise
- Could offset sarcopenia acceleration during perimenopause, but requires resistance training for maximal effect
- GH/IGF-1 stimulation of protein synthesis and satellite cell activation
- Lean mass gain without exercise is modest; resistance training is non-negotiable for meaningful results
- Real but limited without structured training protocol
- Visceral fat loss
- No significant fat mass reduction in clinical trials despite lean mass gain
- Unlikely to reduce visceral adiposity unless combined with caloric deficit and adequate protein intake
- GH has lipolytic effects, but appetite stimulation from ghrelin mimicry offsets this in practice
- Increased hunger makes sustaining a caloric deficit harder, not easier
- Not an effective fat loss tool on its own
- Sleep quality
- Improved REM and slow-wave sleep in young adults; less data in perimenopausal women
- Anecdotal reports of deeper sleep in first 4–6 weeks, but tolerance may develop
- GH release is tightly coupled to slow-wave sleep architecture; MK-677 may enhance this coupling
- Sleep benefits often diminish after 8–12 weeks; not a replacement for progesterone or sleep hygiene
- Possible short-term benefit, but not sustained long-term in most users
- Insulin sensitivity
- Worsens fasting glucose and A1C modestly but consistently across trials
- High-risk in women with prediabetes or metabolic syndrome (common in perimenopause)
- GH antagonizes insulin signaling in liver and adipose tissue
- Women with fasting glucose >100mg/dL should not use MK-677 without CGM monitoring
- Metabolic side effect outweighs benefits in insulin-resistant individuals